Alphabetical listing of all products

  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR


CAN508 was described as a selective inhibitor of transcriptional cyclin-dependent kinase 9. Its cellular effects include decreased phosphorylation of the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.

catalogue number: C021
synonyms: 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol, CDK9 inhibitor II, 31b
CAS: 140651-18-9
MW: 218.2 g/mol

J Med Chem. 2006 Nov 2;49(22):6500-9. PMID: 17064068
Eur J Med Chem. 2011 Sep;46(9):4289-94. PMID: 21777997
ACS Chem Biol. 2012 PMID: 22292676
PDB Structure of its co-crystal with CDK2: 2CLX
PDB Structure of its co-crystal with CDK9/cyclin T: 3TN8